- Home
- HSIC vs JAZZ Comparison
HSIC vs JAZZ Comparison
Compare HSIC & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HSIC
- JAZZ
- Stock Information
- Founded
- HSIC 1932
- JAZZ 2003
- Country
- HSIC United States
- JAZZ Ireland
- Employees
- HSIC N/A
- JAZZ N/A
- Industry
- HSIC Medical Specialities
- JAZZ Biotechnology: Pharmaceutical Preparations
- Sector
- HSIC Health Care
- JAZZ Health Care
- Exchange
- HSIC Nasdaq
- JAZZ Nasdaq
- Market Cap
- HSIC 8.5B
- JAZZ 8.2B
- IPO Year
- HSIC 1995
- JAZZ 2007
- Fundamental
- Price
- HSIC $73.46
- JAZZ $141.45
- Analyst Decision
- HSIC Buy
- JAZZ Strong Buy
- Analyst Count
- HSIC 14
- JAZZ 14
- Target Price
- HSIC $75.71
- JAZZ $179.71
- AVG Volume (30 Days)
- HSIC 1.7M
- JAZZ 739.6K
- Earning Date
- HSIC 11-04-2025
- JAZZ 11-05-2025
- Dividend Yield
- HSIC N/A
- JAZZ N/A
- EPS Growth
- HSIC 30.70
- JAZZ N/A
- EPS
- HSIC 3.17
- JAZZ N/A
- Revenue
- HSIC $12,938,000,000.00
- JAZZ $4,157,832,999.00
- Revenue This Year
- HSIC $4.60
- JAZZ $5.80
- Revenue Next Year
- HSIC $3.44
- JAZZ $6.06
- P/E Ratio
- HSIC $22.99
- JAZZ N/A
- Revenue Growth
- HSIC 3.51
- JAZZ 4.14
- 52 Week Low
- HSIC $60.56
- JAZZ $95.49
- 52 Week High
- HSIC $82.49
- JAZZ $148.06
- Technical
- Relative Strength Index (RSI)
- HSIC 70.31
- JAZZ 61.16
- Support Level
- HSIC $69.13
- JAZZ $128.80
- Resistance Level
- HSIC $73.63
- JAZZ $144.97
- Average True Range (ATR)
- HSIC 1.82
- JAZZ 4.65
- MACD
- HSIC 0.99
- JAZZ -0.13
- Stochastic Oscillator
- HSIC 97.91
- JAZZ 75.14
About HSIC Henry Schein Inc.
Henry Schein Inc is a solutions company for healthcare professionals powered by a network of people and technology. The company is a provider of healthcare products and services to office-based dental and medical practitioners, as well as alternate sites of care. The company's reportable segments are Global Distribution and Value-Added Services; Global Specialty Products; and Global Technology. It generates the majority of its revenue from the Global Distribution and Value-Added Services segment, which includes distribution to the dental and medical markets of national brand and corporate brand merchandise, as well as equipment and related technical services.
About JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.